On Thursday, in the course of current trade, Shares of Threshold Pharmaceuticals Inc. (NASDAQ:THLD), gained 2.85%, and is now trading at $3.97.
Threshold Pharmaceuticals, declared that new clinical data from its ongoing Phase 2 clinical trial evaluating evofosfamide (formerly known as TH-302), an investigational compound, with bortezomib (Velcade®) and dexamethasone in patients with relapsed/refractory multiple myeloma will be presented on Sunday, May 31, 2015, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place May 29 - June 2, 2015, in Chicago, Illinois (Abstract #8579). In addition, a trials-in-progress poster will be presented on the Company’s Phase 2 trial of evofosfamide in patients with advanced melanoma (Abstract #TPS9089).
Abstract #8579 (Poster #397): Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM); Poster Session on Lymphoma and Plasma Cell Disorders, 8:00 AM - 11:30 AM Central Time, Sunday, May 31, 2015, S Hall A.
Abstract #TPS9089 (Poster #327a): A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma; Poster Session on Melanoma/Skin Cancers, 1:15 PM - 4:45 PM Central Time, Monday, June 1, 2015, S Hall A.
Threshold Pharmaceuticals, Inc., a biotechnology company, discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the United States. Its lead investigational small molecule is evofosfamide, which is in two Phase III clinical trials for the treatment of soft tissue sarcoma indication and pancreatic cancer; Phase II clinical trials for treating non-squamous non-small cell lung cancer; Phase II clinical trials for advanced melanoma and soft tissue sarcoma; Phase I/II clinical trials for multiple myeloma and pancreatic cancer; and Phase I clinical trials for the treatment of solid tumors, pancreatic cancer, and advanced solid tumors.
During an Afternoon trade, Shares of Maxim Integrated Products, Inc. (NASDAQ:MXIM), gained 0.43%, and is now trading at $32.66.
Maxim Integrated Products, addressed the need for higher throughput, smaller footprint, and lower power in industrial automation with the MAX14900E digital output switch.
Maxim offers both a complete reference design (MAXREFDES63#) in addition to an evaluation (EV) kit with special prototyping features. The credit-card-sized reference design integrates the MAX14900E, a microcontroller, isolated I/O port, power supplies, UART, and USB port to simplify incorporating the device into the final OEM product design, in addition to provide a means for quick evaluation.
Maxim Integrated Products, Inc. designs, develops, manufactures, and markets various linear and mixed-signal integrated circuits worldwide. The company also provides a range of high-frequency process technologies and capabilities for use in custom designs.
Shares of United Technologies Corporation (NYSE:UTX), during its Thursday’s current trading session gained 1.62%, and is now trading at $119.28.
Sikorsky Aircraft Corp. recently declared its 2015 Supplier of the Year awards and 14 Gold Suppliers recognized for best-in-class performance. The companies all were initially recognized at Sikorsky’s annual Supplier Summit held recently in West Palm Beach, Florida. Sikorsky is a partner of United Technologies Corporation.
The 2015 Supplier of Year award winners are:
- Partnership Award – Stevens Manufacturing, Milford, CT.
- Industrialization Award – Aurora Flight Sciences, Manassas, VA.
- Supplier Performance Award – Parker Hannifin, Irvine, CA
- Innovation Award – Merrill Technologies Group, Saginaw, MI.
- Small Diverse Business Award – Lancaster Packaging Inc., Hudson, MA.
United Technologies Corporation provides technology products and services to building systems and aerospace industries worldwide. Its Otis segment designs, manufactures, sells, and installs passenger and freight elevators, escalators, and moving walkways; modernization products to upgrade elevators and escalators; and maintenance and repair services.
Finally, Century Aluminum Co. (NASDAQ:CENX), gained 0.35% Thursday.
Century Aluminum of Kentucky General Partnership, a partner of Century Aluminum Company, declared that members of USW Local 9423 at its Hawesville, Kentucky smelter rejected the Company’s modified Last, Best, and Final (“LBF”) offer Monday night, May 11, 2015. As a result, a lockout is planned to commence at 8 a.m. CDT on May 12, 2015. The lockout will allow other personnel to maintain uninterrupted plant operations, which is required in the continuous-flow operation of an aluminum smelter. The smelter is fully prepared for the lockout and is predictable to continue to operate safely and at full production.
The Company’s final offer comprised of pay enhances of more than 14 percent during the five-year period, offered fixed costs for health insurance, lower out-of-pocket maximum, and new language on overtime.
Century Aluminum Company, together with its auxiliaries, produces primary aluminum in the United States and Iceland. It produces standard grade and value-added primary aluminum products; and carbon products, such as anodes and cathodes. The company was founded in 1981 and is headquartered in Chicago, Illinois.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
